1. [Stress oxidative in schizophrenia].
- Author
-
Tylec A, Jarzab A, Stryjecka-Zimmer M, and Wójcicka A
- Subjects
- Brain Chemistry drug effects, Catalase metabolism, Free Radicals metabolism, Glutathione Peroxidase metabolism, Humans, Lipid Peroxidation drug effects, Membrane Lipids metabolism, Oxidation-Reduction drug effects, Phospholipids metabolism, Schizophrenia diagnosis, Superoxide Dismutase metabolism, Antioxidants therapeutic use, Neuroprotective Agents therapeutic use, Oxidative Stress drug effects, Schizophrenia drug therapy, Schizophrenia physiopathology
- Abstract
Etiopathogenesis of schizophrenia development is unknown yet in 1% of human population. There is damaged metabolism of biological membranes, abused production of free radicals and altered activity of antioxidant enzymes in patients with schizophrenia. Recently, a study showed that many of the genes and proteins whose expression is modified in the schizophrenic brain are related to glutathione and oxidative stress pathways. According to the researchers changes in permeability of biological membranes in brain could involve the pathophisiology of all--subtypes of schizophrenia as a result of oxidative stress. Brain is particularly sensitive to oxidative damage. There is a lot of phospholipids and polyunsaturated fatty acids in brain tissue under physiological conditions. The changes in polyunsaturated fatty acids metabolism, increased lipid peroxidation and the presence of oxidative stress are found in schizophrenia. They can course to appear instabilities of neuron membranes or even cell death owing to oxidative stress. Mainly to getting to know the molecular disease mechanism is associated with a disorder of the brain. The results suggest that at least some of the schizophrenia disease process can be traced in peripheral tissue like plasma, blood cells or liver. In various types of schizophrenia antipsychotic treatment affects oxidative state of erythrocyte membranes in a different way. Research into changes of antioxidant enzymes level during the treatment of typical and atypical neuroleptic drugs could contribute to widening the knowledge on the reasons of undesirable effects during pharmacotherapy with typical neuroleptic drugs.
- Published
- 2007